[On-Demand] Screen California 2023: Lung Cancer Screening in the Greater Los Angeles Area

Join UCLA experts for an in-depth Lung Cancer Screening Awareness and Best Practices Symposium. This on-demand education features keynote speakers, Drs. Michael Ong, and Ashley Prosper, delivering lectures for CME credit. Topics include patient identification, conducting and documenting shared decision-making, updated screening criteria, and follow-up on abnormal scans. Targeted at primary care providers, pulmonologists, oncologists, researchers, and others interested in lung cancer screening, this comprehensive course also covers best practices, the evaluation of incidental pulmonary nodules, and new frontiers in lung cancer screening, including optimal community engagement.

This series includes 11 videos broken down by topics for ease of viewing.

*This is an on-demand activity that does not have a specific time or location designated for participation. The learners determine whether and when to complete the activity. The content can be assessed at any point during the lifespan of the activity, and there is no specific time designated for participation. 

 
Release Date: 11/18/2024
Termination Date: 11/17/2025

Topics

1. Welcome and Introduction

2. Welcome to UCLA, From the Dean of DGSOM

3. Transformational Possibility of Lung Cancer Screening

4. Pulmonology: Identifying Patients, Options for Biopsy

5. ACS 2023 Guidelines Update

6. Identification of Patients, Counseling Patients, Tobacco Cessation

7. Updates to Eligibility, Management by Nodule Characteristics, Biopsy Options

8. Primary Care Panel-- How Do We Increase Screening: Barriers and Successful Pathways

9. Update on Harms and Safety of Screening

10. Modern Therapeutics Panel: Overcoming Nihilism in Providers and the Public

11. The Future of Lung Cancer Screening

Course Fee: Free

To participate in the activity and obtain Continuing Education (CE) credits, learners should

Register for the Course: Click on the "Register" tab or follow https://ucla.cloud-cme.com/course/courseoverview?P=5&EID=7291&IsExhibitor=false.

1. Access Activity Materials: After completing your registration, view the materials under the "Content" tab.

2. Complete the Post-Test and Course Evaluation: After engaging with the content, please fill out the post-test and course evaluation form.

Your certificate will be available immediately for print or download upon completion.

1. describe updated lung cancer screening criteria
2. discuss screening with patients
3. provide a balanced description of the risks and benefits of screening
4. manage abnormalities found on lung cancer screening
5. utilize resources to improve lung cancer
6. screening to promote earlier diagnosis
7. implement recommended strategies to address barriers to screening related to demographics, psychological and societal issues

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Ericka Cunningham, MBA
UCLA David Geffen School of Medicine

CCPD Staff

Nothing to disclose

Charles Flippen II, MD, FAAN, FANA
David Geffen School of Medicine at UCLA

CCPD Staff

Nothing to disclose

Yunmi Kim
David Geffen School of Medicine at UCLA

CCPD Staff

Nothing to disclose

Kimberly Valencia, CHCP
UCLA David Geffen School of Medicine

CCPD Staff

Nothing to disclose

Jonathan Goldman, MD
UCLA Health

Course Director

Advisor-AstraZeneca (Any division)|Advisor-AbbVie (Any division)|Advisor-Amgen, Inc.|Advisor-Lilly (Any division)|Advisor-Summit

Roshan Bastani, PhD
UCLA

Course Director, Faculty

Nothing to disclose

Amy Cummings, MD, PhD
UCLA Health

Course Director, Faculty

Consulting Fee-AstraZeneca (Any division)|Consulting Fee-Tempus Labs|Consulting Fee-OncoHost (Relationship has ended)

Denise R Aberle, MD
David Geffen School of Medicine at UCLA

Faculty

Grant or research support-Johnson & Johnson|Other: research collabortion-Liquid Diagnostics, LLC|Other: research collaboration-EarlyDx|Other: research collaborator-LungLife AI

Bryan Burt, MD, FACS
UCLA

Faculty

Ownership-bayou surgical

Steven M Dubinett, MD
David Geffen School of Medicine at UCLA

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lung Life AI, Inc.|Stocks or stock options, excluding diversified mutual funds-Lung Life AI, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Early Diagnostics, Inc.|Stocks or stock options, excluding diversified mutual funds-Early Diagnostics, Inc.|Grant or research support-Janssen (Any division)|Grant or research support-Novartis Corporation Pharmaceuticals

Eddie Garon, MD, MS
David Geffen School of Medicine at UCLA

Faculty

Advisor-AbbVie (Any division)|Grant or research support-ABL Bio|Advisor-Arcus (Relationship has ended)|Grant or research support-Arrivent|Grant or research support-AstraZeneca (Any division)|Advisor-AstraZeneca|Advisor-Atreca (Relationship has ended)|Advisor-Bristol-Myers Squibb Company|Grant or research support-Bristol-Myers Squibb|Advisor-BridgeBio|Grant or research support-Daiichi Sankyo, Inc.|Advisor-EMD Serono (Relationship has ended)|Grant or research support-EMD Serono (Relationship has ended)|Advisor-Eli Lilly|Grant or research support-Eli Lilly|Grant or research support-Genentech|Advisor-Genentech (Any division)|Grant or research support-Genentech (Any division)|Advisor-Hookipa (Relationship has ended)|Grant or research support-Iovance|Advisor-Merus (Relationship has ended)|Grant or research support-Mirati|Grant or research support-Novartis Corporation Pharmaceuticals|Advisor-Novartis Corporation Pharmaceuticals|Advisor-Nuvalent|Grant or research support-Regeneron Pharmaceuticals, Inc.|Advisor-Regeneron Pharmaceuticals, Inc.|Advisor-Seagan (Relationship has ended)|Advisor-Sanofi (Relationship has ended)|Advisor-Sensei (Relationship has ended)|Advisor-Sumitomo (Relationship has ended)|Advisor-Summit|Advisor-Synthkine|Grant or research support-synthekine|Advisor-Zymeworks (Relationship has ended)

Alan Lee, MD
UCLA

Faculty

Consulting Fee-Oncohost (Relationship has ended)|Consulting Fee-Intuitive Surgical (Relationship has ended)

Jay Lee, MD
UCLA

Faculty

Advisor-AstraZeneca (Any division)

Carol Mangione, MD, MSPH, FACP
David Geffen School of Medicine at the University of California, Los Angeles (UCLA)

Faculty

Nothing to disclose

Anjani Mattai, MD
UCLA Health

Faculty

Nothing to disclose

Drew Moghanaki, MD
DGSOM

Faculty

Honoraria-AstraZeneca (Any division)|Consulting Fee-Delfi Diagnostics (Relationship has ended)|Honoraria-Varian|Consulting Fee-ViewRay (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-LungLifeAI|Honoraria-Bristol-Myers Squibb Company (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck (Any division) Merck (Any division) (Relationship has ended)

Catherine Oberg, MD
MSKCC

Faculty

Consulting Fee-Intuitive|Consulting Fee-Medtronic (Relationship has ended)|Consulting Fee-Cook Medical

Michael K Ong, MD, PhD, FACP
UCLA

Faculty

Nothing to disclose

Ashley E Prosper, MD
UCLA Department of Radiological Sciences

Faculty

Consulting Fee-MedQIA (Relationship has ended)|Honoraria-LA Care (Relationship has ended)|Honoraria-Canon Medical (Relationship has ended)

Tina Shih, PhD
UCLA

Faculty

Consulting Fee-Sanofi

Neil Wenger, MD, MPH
UCLA David Geffen School of Medicine

Faculty

Nothing to disclose

Dannyael Hamilton, Bachelor of Science
UCLA

Other Planning Committee Member

Nothing to disclose